UMC Utrecht and VectorY Therapeutics collaborate in ALS Biomarker Study

Finding these biomarkers is expected to help diagnose ALS and monitor disease progression and improve the design of future clinical studie

18-Jun-2024 - UMC Utrecht has enrolled its first patient for a new study to identify biomarkers of Amyotrophic Lateral Sclerosis (ALS). The observational investigator-initiated study is led by Professor Dr. Leonard van den Berg and supported by VectorY Therapeutics. VectorY Therapeutics is developing ...

Gene therapy start-up VectorY and Wageningen University sign strategic collaboration

Two-part project to develop novel baculovirus genome seeds and bioprocess technologies for the scalable production of AAV gene therapies

27-Jan-2022 - VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of muscular and neurodegenerative disorders through vectorized antibodies, announces a collaboration with Wageningen University to develop novel baculovirus-based ...

VectorY raises €31 million in seed financing to develop next-generation gene therapies aimed at muscular and CNS disorders

17-Jun-2021 - VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of muscular and neurodegenerative disorders through vectorized antibodies, announces the completion of a €31 million seed financing round. The oversubscribed round was ...

Development of a small molecule that inhibits the replication of SARS-CoV-2 and other RNA viruses

Forbion invests USD 2.3M in seed financing of CoviCept Therapeutics

22-Jan-2021 - Forbion, a European life sciences venture capital firm, announces a $2.3m seed investment in newly formed CoviCept Therapeutics, Inc., a California-based company that is developing a small molecule that inhibits the replication of SARS-CoV-2 (COVID-19) and other RNA viruses. CoviCept’s lead ...

Abzena invests in expansion of biotherapeutics and makes executive appointment

07-Nov-2018 - Dr. Jonathan Goldman, CEO, announced that Abzena has augmented existing 500 L scale biologics equipment with $20M of investment into two new manufacturing suites at 500 L and 2000 L scale in a new GMP facility in San Diego, which will be equipped with Sartorius single use bioreactors. Abzena’s ...

Forbion Closes Oversubscribed Fourth Life Sciences VC Fund at EUR 360 million

Investment focus is on new drugs and technologies

02-Oct-2018 - Forbion has announced the final close of its new flagship fund, Forbion IV. The oversubscribed fund closed at EUR 360 million in capital commitments, significantly above its original target of EUR 250 million. Forbion IV, like its predecessor fund, Forbion III, will primarily focus on ...

First neuroblastoma patient successfully dosed with innovative CAR therapy utilizing natural killer T cells (CAR-NKT)

24-Sep-2018 - Cell Medica announces the treatment of the first patient world-wide to receive CMD-501, an autologous CAR-NKT therapy targeting pediatric neuroblastoma. This is the first time an engineered NKT cell therapy has been used in humans. Cell Medica is a clinical-stage biopharmaceutical company that is ...

Crescendo Biologics Ltd. Raises $70 Million in Series B Financing

02-May-2018 - Crescendo Biologics Ltd announced that it has completed a $70 million (€57 million) Series B financing. The funds will be used to advance the development of its lead programme, CB307, which stimulates local activation of tumour-specific T-cells, into the clinic and further expand its internal ...

Crescendo Biologics first major milestone in collaboration with Takeda reached

18-Apr-2018 - Crescendo Biologics Ltd, the developer of multifunctional biologics, including targeted T-cell engagers, announced that it has achieved the first major technical milestone under the terms of its collaboration with Takeda Pharmaceutical Company Limited. The global, strategic, multi-target ...

Abzena takes on new facilities

09-Jan-2018 - Abzena plc enables the development and manufacture of biopharmaceutical products,provides an update on its UK and US facilities. In Cambridge, UK, the Group’s lease has commenced for 30,000 square feet of space in Building 900 on the Babraham Research Campus, as first announced in February 2015. ...